Q-omics provides the consensus-scored ZSWIM4 profile across patient tissues and cancer cell-line models. ZSWIM4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZSWIM4 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, ZSWIM4 RNA expression shows 19,094 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, COAD, and ACC as cancer lineages where ZSWIM4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZSWIM4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZSWIM4 survival associations across molecular data types. ZSWIM4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZSWIM4 RNA expression–survival associations across cancer types. High ZSWIM4 expression shows unfavorable associations in ACC, MESO, KIRP and LIHC, but favorable associations in HNSC and SCLC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZSWIM4 RNA expression.
This table summarizes ZSWIM4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZSWIM4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZSWIM4 shows lower tumor expression in KICH and higher tumor expression in COAD, STAD, BLCA, LUAD and READ. The COAD box plot shows higher ZSWIM4 RNA expression in tumor versus normal tissue (log2 FC = +1.734, t-test p < 0.001).
This table shows molecular features associated with ZSWIM4 in patient tissues and cancer cell lines. In patient samples, ZSWIM4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZSWIM4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
